These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 10885901)

  • 1. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
    Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
    Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
    Kruczynski A; Hill BT
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.
    Okouneva T; Hill BT; Wilson L; Jordan MA
    Mol Cancer Ther; 2003 May; 2(5):427-36. PubMed ID: 12748304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
    Lobert S; Puozzo C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of inhibition of cell proliferation by Vinca alkaloids.
    Jordan MA; Thrower D; Wilson L
    Cancer Res; 1991 Apr; 51(8):2212-22. PubMed ID: 2009540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway.
    Pourroy B; Carré M; Honoré S; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
    Mol Pharmacol; 2004 Sep; 66(3):580-91. PubMed ID: 15322250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
    Jordan MA; Himes RH; Wilson L
    Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
    Pourroy B; Honoré S; Pasquier E; Bourgarel-Rey V; Kruczynski A; Briand C; Braguer D
    Cancer Res; 2006 Mar; 66(6):3256-63. PubMed ID: 16540678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant decrease of resistance and modifications of the cytoskeleton after all-trans retinoic acid and phorbol ester treatments in a navelbine-resistant bladder carcinoma cell line.
    Debal V; Breillout F; Manfait M
    Anticancer Res; 1997; 17(2A):1147-54. PubMed ID: 9137463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.
    Kruczynski A; Poli M; Dossi R; Chazottes E; Berrichon G; Ricome C; Giavazzi R; Hill BT; Taraboletti G
    Eur J Cancer; 2006 Nov; 42(16):2821-32. PubMed ID: 16973349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M; Tanaka N
    In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
    Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.